This is great news! Breast cancers were reduced by 7% in a very broad sense after the use of hormone therapy was greatly reduced.
I don't think this is old news, as statistics tend to lag events by a few years, so it wasn't really , likely due to reduced
One side effect of this news: the patient population for Herceptin (Erb-b2+) will happily decline slightly. Even with the reduced incidence rate, Genentech and BMS will still have good markets for their targeted products (Herceptin and Tykerb, respectively.)
Sunday, December 17, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment